What's Next: In its January 2024 earnings call, Dexcom noted that it will launch the product in summer 2024. While no exact price has been mentioned by Dexcom as of yet, Kevin R. Sayer- the company's CEO – stated that the price of the device will be competitive. The primary competitor of the device is Abbott's Lingo, that is currently available in the UK for under USD100 per two-week supply. Consequently, we anticipate the Stelo device will be priced competitively in a similar range. We expect insurance providers will extend their coverage to the Stelo device in the short–to-medium term, which we expect to increase accessibility further. In the longer term, we expect that this, and subsequent expected approvals alike, will support remote healthcare and drive outpatient care. This is because patients are likely to be more informed and have greater autonomy over their health to make independent decisions to maintain and promote their well-being.